CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.
Carcinoembryonic antigen T cell bispecific antibody (CEA TCB) is a bispecific antibody used to recognize CEA and CD3e via a novel molecular format (2:1) that induces T cell-mediated killing of CEA over-expressing tumors while sparing primary cells with low CEA expression. CEA TCB treatment inhibits tumor growth and generates a highly inflamed tumor microenvironment.
Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland.
Marina
M
Bacac
Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland.
Christian
C
Klein
Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland.
Pablo
P
Umana
Bispecific; T cell